SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kyntra Bio shifts strategy toward roxadustat after ending FG-3246 program

Kyntra Bio presented a roxadustat-focused strategy after ending its FG-3246 program.

KYNB

Related stories